1. Hu S, Zhu L, Zhang X. Resolving heterogeneity in first-episode and drug-naive major depressive disorder based on individualized structural covariance network: evidence from the REST-meta-MDD consortium. Psychological Medicine 2025; 55:e174.
2. Yi Z, Xia L, Yi J, Jia Y, Wei L, Shen S, Wu N, Wang D, Zhou H, Li X, Yan CG, Zhang XY. Structural brain changes in the anterior cingulate cortex of major depressive disorder individuals with suicidal ideation: Evidence from the REST-meta-MDD project. Psychological Medicine 2025;55:e24.
3. Zhou D, Li X, Wei S, Yu C, Wang D, Li Y, Li J, Liu J, Li S, Zhuang W, Li Y, Luo R, Liu Z, Liu J, Xu Y, Fan J, Zhu G, Xu W, Tang Y, Cho RY, Kosten TR, Zhang XY. Transcranial Direct Current Stimulation Combined With Repetitive Transcranial Magnetic Stimulation for Depression: A Randomized Clinical Trial. JAMA Network Open 2024; 7(11):e2444306.
4. Li ZZ, Chen YP, Zang XC, Zheng D, Lang XE, Zhou YJ, Wu FC, Zhang XY. Sexual dimorphism in the relationship between BMI and recent suicidal attempts in first-episode drug-naïve patients with major depressive disorder. Military Medical Research 2024; 11(1):66.
5. Liu L, Li Z, Kong D, Huang Y, Wu D, Zhao H, Gao X, Zhang X, Yang M. Neuroimaging markers of aberrant brain activity and treatment response in schizophrenia patients based on brain complexity. Translational Psychiatry 2024; 14(1):365.
6. Wang D, Tian Y, Chen J, Zhu R, Li J, Zhou H, Chen D, Wang L, Kosten TR, Zhang XY. Ginkgo biloba for Tardive Dyskinesia and Plasma MnSOD Activity: Association with MnSOD Ala-9Val Variant. Current Neuropharmacology 2024;22(14):2443-2452.
7. Li X, Liu J, Wei S, Yu C, Wang D, Li Y, Li J, Zhuang W, Luo RC, Li Y, Liu Z, Su Y, Liu J, Xu Y, Fan J, Zhu G, Xu W, Tang Y, Yan H, Cho RY, Kosten TR, Zhou D, Zhang X. Cognitive enhancing effect of rTMS combined with tDCS in patients with major depressive disorder: a double-blind, randomized, sham-controlled study. BMC Medicine 2024 22(1):253.
8. Wang DM, Chen DC, Xiu MH, Wang L, Kosten TR, Zhang XY. A double-blind, randomized controlled study of the effects of celecoxib on clinical symptoms and cognitive impairment in patients with drug-naïve first episode schizophrenia: pharmacogenetic impact of cyclooxygenase-2 functional polymorphisms. Neuropsychopharmacology 2024;49(5):893-902
9. Gao Z, Xiu M, Liu J, Wu F, Zhang X. Smoking, Symptoms Improvement, and Total Antioxidant Capacity in Patients with Drug-naive First-episode Schizophrenia: A Prospective Cohort Study. Current Neuropharmacology 2024;22(10):1733-1741
10. Song X, Xiu M, Yang H, Huang X, Wu F, Zhang X. Smoking Affects the Predictive Roles of Antioxidant Enzymes in the Clinical Response to Risperidone in Schizophrenia: A Large-scale Cohort Study. Current Neuropharmacology 2023;21(10):2151-2158
11. Shen H, Ge L, Cao B, Wei GX, Zhang X. The contribution of the cingulate cortex: treating depressive symptoms in first-episode drug naïve schizophrenia. The International Journal of Clinical and Health Psychology 2023; 23(3):100372.
12. Qu M, Yang K, Cao Y, Wang X, Tan S, Xiu M, Zhang X. Symptoms of Anxiety and Depression Among Adolescents Before vs During COVID-19-Related School Closures in China. JAMA Network Open 2022; 5(11):e2241752.
13.Liu H, Liu H, Jiang S, Su L, Lu Y, Chen Z, Li X, Li X, Wang X, Xiu M, Zhang X. Sex-specific association between antioxidant defense system and therapeutic response to risperidone in schizophrenia: a prospective longitudinal study. Current Neuropharmacology 2022; 20(9):1793-1803
14. Liu H, Yu R, Gao Y, Li X, Guan X, Thomas K, Xiu M, Zhang X. Antioxidant enzymes and weight gain in drug-naive first episode schizophrenia patients treated with risperidone for 12 weeks: a prospective longitudinal study. Current Neuropharmacology 2022; 20(9):1774-1782
15. Chen YQ, Li XR, Zhang L, Zhu WB, Wu YQ, Guan XN, Xiu MH, Zhang XY. Therapeutic Response Is Associated With Antipsychotic-Induced Weight Gain in Drug-Naive First-Episode Patients With Schizophrenia: An 8-Week Prospective Study. Journal of Clinical Psychiatry 2021 May 11;82(3):20m13469.
16. Zhou Y, Ren W, Sun Q, Yu KM, Lang X, Li Z, Zhang XY. The association of clinical correlates, metabolic parameters, and thyroid hormones with suicide attempts in first-episode and drug-naïve patients with major depressive disorder comorbid with anxiety: a large-scale cross-sectional study. Translational Psychiatry 2021 Feb 4;11(1):97.
17. Zhang XY, Yang M, Du X, Liao W, Chen D, Fan F, Xiu M, Jia Q, Ning Y, Huang X, Wu F, Soares JC, Cao B, Wang L, Chen H. Glucose disturbances, cognitive deficits and white matter abnormalities in first-episode drug-naive schizophrenia. Molecular Psychiatry 2020;25(12):3220-3230
18. Yang M, Gao S, Zhang X. Cognitive deficits and white matter abnormalities in never- treated first-episode schizophrenia. Translational Psychiatry 2020; 10(1):368.
19. Shi H, Liu Z, Peng S, Wang R, Qi L, Li Z, Yang J, Ren Y, Song X, Zeng L, Qian W, Zhang XY. The prevalence of psychiatric symptoms of pregnant and non-pregnant women during the COVID-19 epidemic. Translational Psychiatry 2020; 10(1):319.
20.Cao B, Cho RY, Chen D, Xiu M, Wang L, Soares JC, Zhang XY. Treatment response prediction and individualized identification of first-episode drug-naïve schizophrenia using brain functional connectivity. Molecular Psychiatry 2020; 25(4):906-913
21. Xiu MH, Li Z, Curbo ME, Wu HE, Chen DC, Chen S, Tong YS, Tan SP, Zhang XY. Interrelationships between BDNF, superoxide dismutase and cognitive impairment in first episode drug-naive patients with schizophrenia. Schizophrenia Bulletin 2020; 46(6):1498-1510
22. Du X, Yin M, Yuan L, Zhang G, Fan Y, Li Z,Yuan N, Lv X, Zhao X, Zou S, Deng W, Kosten TR, Zhang XY. Reduction of depression-like behavior in rat model induced by ShRNA targeting norepinephrine transporter in locus coeruleus. Translational Psychiatry 2020; 10(1):130.
23. Xia L, Liu L, Hong X, Wang D, Wei G, Wang J, Zhou H, Xu H, Tian Y, Dai Q, Wu HE, Chang C, Wang L, Kosten TR, Zhang XY. One-day tropisetron treatment improves cognitive deficits and P50 inhibition deficits in schizophrenia. Neuropsychopharmacology 2020; 45(8):1362-1368
24. Xiu MH,Guan HY,Zhao JM,Wang KQ,Pan YF,Su XR,Wang YH,Guo JM,Jiang L, Liu HY,Sun SG,Wu HR,Liu XW,Yu HJ,Wei BC,Li XP,Trinh T,Tan SP, Zhang XY. Cognitive Enhancing Effect of High-Frequency Neuronavigated rTMS in Chronic Schizophrenia Patients With Predominant Negative Symptoms: A Double-Blind Controlled 32-Week Follow-up Study.Schizophrenia Bulletin 2020; 46(5):1219-1230
25. Guan HY, Zhao JM, Wang KQ, Su XR, Pan YF, Guo JM, Jiang L, Wang YH, Liu HY, Sun SG, Wu HR, Ren YP, Geng HS, Liu XW, Yu HJ, Wei BC, Li XP, Wu HE, Tan SP, Xiu MH, Zhang XY. High-frequency neuronavigated rTMS effect on clinical symptoms and cognitive dysfunction: a pilot double-blind, randomized controlled study in Veterans with schizophrenia. Translational Psychiatry 2020; 10(1):79.
26. Zhou Y, Li Y, Meng Y, Wang J, Wu F, Ning Y, Li Y, Cassidy RM, Li Z, Zhang XY. Neuregulin 3 rs10748842 polymorphism contributes to the effect of body mass index on cognitive impairment in patients with schizophrenia. Translational Psychiatry 2020; 10(1):62.
27. Wei CW, Chen YQ, Ma M, Xiu MH, Zhang XY. Sex differences in the association of body mass index with symptoms and cognitive deficits in Chinese patients with chronic schizophrenia. Translational Psychiatry 2020 10:18
28. Wang DM, Zhang XY. Sex differences in the prevalence and clinical features of comorbid depressive symptoms in patients with never-treated, first-episode schizophrenia. The Lancet 2019; 394 (Supp.): S84
29. Chen DC, Yang KB, Nie Y, Wang N, Li YL, Xiu MH, He SC, Yang FD, Kosten TR, Soares JC, Zhang XY. Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia: relationships to clinical phenotypes and cognitive deficits. Psychological Medicine 2016; 46(15):3219-3230.
30.Xiu MH, Tian L, Chen S, Tan YL, Chen DC, Chen J. Chen N, Yang FD, Licinio J, Kosten TR. Soares JC, Zhang XY. Contribution of IL-10 and its -592 A/C polymorphism to cognitive functions in first-episode drug-naive schizophrenia. Brain Behavior and Immunity 2016;57:116-124 31. Zhang XY, Tan YL, Chen DC, Tan SP, Yang FD, Wu HE, Zunta-Soares GB, Kosten TR, Huang XF, Soares JC. Interaction of BDNF with cytokines in chronic schizophrenia. Brain, Behavior and Immunity 2016; 51: 169-175
32.Wang L, Cao C, Wang W, Xu H, Zhang J, Deng H, Zhang XY. Linking Hair Cortisol Levels to Phenotypic Heterogeneity of Posttraumatic Stress Symptoms in Highly Traumatized Chinese Women. Biological Psychiatry 2015; 77(4):e21-22
33.Zhang XY, Chen da C, Xiu MH, Yang FD, Tan YL, Luo X, Zuo L, Kosten TA, Kosten TR. Cognitive function, plasma manganese superoxide dismutase (MnSOD) and MnSODAla-9Val polymorphism in patients with schizophrenia and normal controls. Schizophrenia Bulletin 2014; 40(3): 592-601
34. Zhang XY, Liu L, Liu S, Hong X, Chen DC, Xiu MH, Kosten TA, Kosten TR. Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia. American Journal of Psychiatry 2012; 169：974-981
35. Zhang XY, Chen DC, Xiu MH, Haile CN, Zhang HP, Luo X, Xu K, Kosten TA, Kosten TR. Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba . Biological Psychiatry 2012; 72: 700-706
36. Zhang XY, Tan YL, Zhou DF, Haile CN, Wu GY, Cao LY, Kosten TA, Kosten TR. Nicotine dependence, symptoms and oxidative stress in male patients with schizophrenia. Neuropsychopharmacology 32:2020-2024 (2007).
37. Zhang XY, Tan YL, Zhou DF, Cao LY, Wu GY, Haile CN, Kosten TA, Kosten TR. Nicotine dependence, symptoms, and oxidative stress in male patients with schizophrenia. Neuropsychopharmacology 32 (9), 2020-2024, (2007)
38. Zhang XY, Kosten TA. Previous exposure to cocaine enhances cocaine self-administration in an alpha 1-adrenergic receptor dependent manner. Neuropsychopharmacology 32:638-645 (2007).
39. Zhang XY, Kosten TA. Prazosin, an alpha-1 adrenergic antagonist, reduces cocaine-induced reinstatement of drug-seeking. Biological Psychiatry 57:1202-1024 (2005).
40. Zhang XY, Haile CN, Tan YL, Zuo LJ, Yang BZ, Cao LY, Zhou DF. Tumour necrosis factor alpha polymorphism (-1031T/C) is associated with age of onset of schizophrenia. Molecular Psychiatry 10:897-899 (2005).
41. Zhang XY, Zhou DF, Cao LY, Wu GY, Shen YC. Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics. Neuropsychopharmacology 30:1532-1538 (2005).
